AFFX Affymetrix, Inc.

The Affymetrix Microarray Bulletin (AMB) today published interviews with researchers from Lawrence Berkeley National Laboratory and The Naval Medical Research Center, who are using Affymetrix (Nasdaq:AFFX) microarrays to detect thousands of different pathogens, including anthrax and plague. Researchers Find Pathogens in Unlikely Places Using High-density Microarrays LBNL's Gary Andersen discusses the surprising organisms they are finding in normal environmental samples Anthrax Genetic Discovery Provides Basis for New Biodefense Test NMRC's Michael Zwick and Timothy Read discuss how microarrays that resequence the entire anthrax genome may help the military detect novel anthrax strains To view the complete stories, please visit: http://microarraybulletin.com/community. Affymetrix Microarray Bulletin (AMB) is a magazine published by Affymetrix, Inc. (Nasdaq:AFFX) that highlights leading microarray research and diagnostic developments around the world. AMB features interviews by and for scientists, statisticians and software engineers -- one expert interviewing another. Our goal is to create a forum where this community can discuss research and share new resources and information. For more information about AMB, please visit the publication's website at www.microarraybulletin.com. About Affymetrix: Affymetrix scientists invented the world's first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,300 systems have been installed around the world and nearly 4,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif. with subsidiaries in Europe and Asia, as well as manufacturing facilities in Sacramento, Calif. and Bedford, Mass. The company has about 1,000 employees worldwide. For more information about Affymetrix, please visit the company's website at www.Affymetrix.com. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix Inc.